Biodel - Marlboro für das Depot?

das nervt immer überall die Prozente zu posten...


vorallem nur bei plus ;-) mach mal bei gbsn weiter, hmm


man kann es ja mal machen, aber du bist ein bisschen inflationär !!

 

"We look forward to reporting the topline data from Study 3-157 towards the end of the first calendar quarter of 2016."

http://investor.biodel.com/releasedetail.cfm?ReleaseID=940285

KK  

am Donnerstag rockts.

Umsatz zieht auch an!

KK  

http://www.watchlistnews.com/...zacks-investment-research/588234.html

KK  

 

 

http://civilinquiry.jud.ct.gov/DocumentInquiry/...DocumentNo=10257380

KK  

kannst du mir das bitte kurz zusammen fassen um was es da geht?  

Hypoglycemia Pipeline 2016 H1 Market Research and Review Report

PR Newswire

PUNE, India, March 31, 2016

PUNE, India, March 31, 2016 /PRNewswire/ --

RnRMarketResearch.com adds "Hypoglycemia - Pipeline Review, H1 2016" market research report with comprehensive information on the therapeutic development for Hypoglycemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypoglycemia and special features on late-stage and discontinued projects.

Complete report on H1 2016 pipeline review of Hypoglycemia with 27 market data tables and 13 figures, spread across 75 pages is available at http://www.rnrmarketresearch.com/...review-h1-2016-market-report.html  

The report also reviews key players involved in the therapeutic development for Hypoglycemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies discussed in this Hypoglycemia Pipeline Review, H1 2016 report include Biodel Inc., Eiger BioPharmaceuticals, Inc., Eli Lilly and Company, Heptares Therapeutics Limited, Novartis AG, Sanofi, SkyePharma Plc, Therakind Limited, USV Limited, XERIS Pharmaceuticals, Inc., XOMA Corporation and Zealand Pharma A/S. Drug profiles discussed in this research report includes AMG-5041, Biologic for Hypoglycemia, Drug for Hypoglycemia, exendin-(9-39), glucagon, LY-3143753, LY-3185643, pasireotide, SAR-438544, Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia, terbutaline sulphate MR, XOMA-129, XOMA-358 and ZP-4207.

Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=516303  

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Hypoglycemia and reviews pipeline therapeutics for Hypoglycemia by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Hypoglycemia therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Hypoglycemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Hypoglycemia.

Another newly published market research report titled on Insulin Resistance - Pipeline Review, H1 2016 provides comprehensive information on the therapeutic development for Insulin Resistance, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insulin Resistance and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Insulin Resistance Pipeline market research report of 62 pages is available at http://www.rnrmarketresearch.com/...review-h1-2016-market-report.html  

Explore more reports on Diabetes Therapeutics .

About Us:  

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

http://www.bizjournals.com/prnewswire/.../2016/03/31/enUK201603309159  

Is this court case just the tip of the "iceberg"?

http://hotcopper.com.au/threads/...mp;direction=previous#.Vv0RpnpuF0Q

KK;-)  

How Biodel (BIOD) trades after earning announcements?

 By Richard Viskan On April 1, 2016



 

 





 








 



Biodel Inc. (NASDAQ:BIOD) is expected to announce second quarter financial results estimated on 05/04/2016. The company added about 13 percent in value since last earnings when it was at $. Based on the most relevant historical data, there is a 50 percent probability for share price to go down following the next earnings report. Looking further into earnings reaction history, the stock had moved up 12 times out of last 24 quarters. It has topped earnings-per-share estimates 41% of the time in its last 12 earnings reports. It missed earnings on 6 occasions, and it has met expectations 0 times.

So how did BIOD’s earnings announcements affect its stock price in the past few quarters?

Biodel Inc. (BIOD) Earnings Reaction History

Overall, the average earnings surprise was 37.53 percent over the past four quarters. Back on February 16, 2016, it posted earnings per share at $-0.05 which topped the consensus $-0.08 projection (positive surprise of 37.5%). Revenue came in at 0M versus consensus estimate of 0M. The stock dropped 0 percent the day following the earnings was released, and on 7th day price change was 0 percent.

On December 17, 2015, it posted earnings per share at $0 versus the consensus estimate of $-0.11 (positive surprise of 100%). Revenue of 0M was below the $0M analysts had expected. The stock gained 34.78% the day following the earnings was released, and on 7th day price change was 26.09%.

On August 13, 2015, it posted earnings per share at $-0.12, missing the consensus estimate of $-0.11 (negative surprise of -9.1%). Revenue for the quarter was $0M while analysts had expected revenues to come in at $0M. The stock dropped -23.16% the day following the earnings was released, and on 7th day price change was -28.42%.

On May 6, 2015, it posted earnings per share at $-0.18 compared with the consensus estimate of $-0.23 (positive surprise of 21.7%). That came on revenues of $0M for the quarter. Analysts had expected $0M in revenue.

Biodel Inc. Earnings Expectations

In front of Q2 earnings release, Wall Street is expecting earnings per share of $-0.07. The analysts’ current consensus range is $-0.1-$-0.04 for EPS.

Biodel Inc. (NASDAQ:BIOD) last closed at $0.33, sending the company’s market cap around $21.19M. The consensus 12-month price target from brokerage firms covering the stock is $3.5. The share price has declined -75.37% from its best level in 52 weeks and advanced -2.94% this year. It recently traded in a range of $0.33-$0.35 at a volume of 699083 shares. The stock ended last trading session nearly -2.94 lower for the last 21 trading days, rebounding 50% from its 52-week low.




http://www.zergwatch.com/2016/04/01/...s-after-earning-announcements/

KK  

http://investor.biodel.com/...ilingid=1145443-16-1713&CIK=1322505  

0,35 / 0,45
sieht schon mal gut aus.
:-)

 

Several insulin products in development are reported to have a time-action profile that is more rapid than that of the currently availableinjected rapid-acting insulin analogs. For example, Novo Nordisk is developing NN1218, an insulin analog that is intended to provide faster onset of action than aspart. NN1218 is currently undergoing regulatory review in the United States andEurope. In addition, Biodel, Inc. has conducted a Phase 2 clinical trial of BIOD-123, a formulation of human insulin with certain excipients that increase the rate of absorption following injection.

http://www.getfilings.com/sec-filings/160315/MANNKIND-CORP_10-K/


Biodel hat definitiv eine sehr gute Pipeline. Und da gibt es Kohlen für!!

KK
 

 

 

 

 

- ggf. bald anstehender Merger
- kürzlich Nasdaq Listing Verlängerung um 180 Tage
- Analysten sehen Kursziel bei 0,29 USD

... zumindest bewegt sich mal was und entsprechende News sind auch da :-) Warten wirs ab ... zumindest meiner Einschätzung nach aussichtsreicher als Atossa  

 

Kursziel von Ladenburg Thalmann ist von 4 auf 3,50 Dollar gesenkt.

Und diese unterstützen jetzt beim Merger!

KK  

wenn die den Laden darunter verscherbeln! Dann ....

KK  

Roth bei 5 Dollar

http://www.finanzen.at/analyse/Biodel-Buy-539596

Ladenburg Thalmann  bei 3,50 Dollar

http://www.moneyflowindex.org/...denburg-thalmann-to-neutral/3214089/

KK


 

korrektur. mmn leichter Abgang bis 29-27. (April?) klar glaubt das keiner. aber man könnte den gewinn in Atom kurzeitig erst mal verlagern. viel zu schön um wahr zu sein. ist ja schon ekelhaft so viel push zu hören?

alles gute den mit versierten  

...drin. Bleibe weiter dabei...

Gruß vom
Advamillionär